Hetero has launched its generic semaglutide portfolio in overseas markets even as it is awaiting regulatory approvals in India. The launch represents the beginning of a strategic, multi-year global ...

Actress and hands-on mom Judy Ann Santos, together with her mother, Mommy Carol, headlines the campaign—underscoring the multi-generational trust in TGP Generics. TGP reminds Filipinos why it remains ...

https://www.thehindubusinessline.com/companies/natco-pharma-launches-generic-semaglutide-injection-in-india/article70764288.ece Copy Natco Pharma has launched the ...

With patents expiring today in India for Novo Nordisk’s popular diabetes and obesity drugs Ozempic and Wegovy, more than 40 generic drug makers are expected to begin launching their cheaper versions ...

India’s weight-loss drug market is on the verge of a price shake-up. In days, domestic drugmakers are set to launch cheaper versions of semaglutide, the GLP-1 (glucagon-like peptide-1) therapy popular ...

At least a dozen large Indian drugmakers are set to roll out copies of Novo Nordisk A/S’s blockbuster weight-loss drugs as soon as the patent expires Friday, crashing prices in the country with the ...

The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...

MUMBAI – A deluge of weight-loss drugs is set to transform the global fight against obesity, as India prepares to unleash low-cost generic versions of injections like Ozempic after a key patent ...

Danish pharma giant Novo Nordisk has once again reduced the prices of its blockbuster drugs Ozempic and Wegovy in India. The strategic move is aimed at staying ahead of the entry of the low-cost ...

NEW DELHI: With prices of GLP-1 drugs crashing and their generic versions flooding the market, govt has cracked down on their misuse, inspecting 49 businesses and issuing notices while also flagging ...

March 31 (Reuters) - Novo Nordisk on Tuesday cut the prices of its diabetes and weight-loss drugs Ozempic and Wegovy by as much as 36% and 48% in India, its second such move, to fend off competition ...